Epigenetics. Synergy. Survival. 🧬💊📈 in in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma

from Dr RR Baliga's "Got Knowledge Doc" Podkast · host MasterMedFacts LLC

A pivotal JAMA randomized trial introduces an epigenetic twist to frontline therapy in high-risk DLBCL. Adding tucidinostat (HDAC inhibitor) to R-CHOP improved event-free survival (HR 0.72, P=0.02) and increased complete response rates (73% vs 62%) in MYC/BCL2 double-expressor lymphoma. Toxicity was higher but manageable. A quiet but meaningful shift—targeting biology, not just burden. #DLBCL #Lymphoma #Oncology #PrecisionMedicine #JAMA #ClinicalTrials

Episode metadata supplied by the publisher feed · Published Apr 24, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Epigenetics. Synergy. Survival. 🧬💊📈 in in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma

0:00 4:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Dr RR Baliga's "Got Knowledge Doc" Podkast?

This episode is 4 minutes long.

When was this Dr RR Baliga's "Got Knowledge Doc" Podkast episode published?

This episode was published on April 24, 2026.

Can I download this Dr RR Baliga's "Got Knowledge Doc" Podkast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!